← back to search

Paul F. Pollack

Eli Lilly (United States) · US
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Rheumatoid Arthritis Research and Therapies, and Eosinophilic Esophagitis.
h-index
24
citations
5,936
works
60
NIH funding
primary concept
Adalimumab
email

Recent publications

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease
Gastroenterology 2021cited by 144position: middledoi
Adalimumab Induces Deep Remission in Patients With Crohn's Disease
Clinical Gastroenterology and Hepatology 2013cited by 246position: middledoi
Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
Gastroenterology 2013cited by 190position: middledoi
Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
Inflammatory Bowel Diseases 2013cited by 122position: middledoi
52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants
Inflammatory Bowel Diseases 2013cited by 111position: middledoi
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Gastroenterology 2012cited by 578position: middledoi
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial
Journal of Crohn s and Colitis 2012cited by 58position: middledoi

Grants

Statistical Questions in Number Theory and Arithmetic Geometry
NSF2001581$168,0002020–2025PIRePORTER
Elementary, analytic, and algorithmic number theory: Research inspired by the mathematics of Carl Pomerance
NSF1502336$19,7282015–2016PIRePORTER
Statistical problems in elementary, analytic, and algebraic number theory
NSF1402268$130,2952014–2019PIRePORTER
PostDoctoral Research Fellowship
NSF0802970$108,0002008–2012PIRePORTER

Frequent collaborators

William J. Sandborn · Mirati Therapeutics (United States)5 papers (2012–2021)Roopal Thakkar · University of Regina3 papers (2013–2013)Anne Camez · AbbVie (United States)3 papers (2012–2013)Walter Reinisch · Reed Medical (United Kingdom)3 papers (2012–2013)Anne Robinson · Neogen (United States)3 papers (2013–2013)Andreas Lazar · AbbVie (United States)2 papers (2012–2013)Parvez Mulani · AbbVie (United States)2 papers (2012–2013)Geert D’Haens · Vrije Universiteit Amsterdam2 papers (2012–2021)Naijun Chen · AbbVie (United States)2 papers (2012–2013)Édouard Louis · Centre Hospitalier Universitaire de Liège2 papers (2012–2013)Bidan Huang · Qingdao University2 papers (2013–2013)Kathleen G. Lomax · AbbVie (United States)2 papers (2012–2013)Jingdong Chao · AbbVie (United States)2 papers (2012–2013)Paul Rutgeerts · KU Leuven2 papers (2012–2013)Jean–Frédéric Colombel · University Hospital Medical Center Bezanijska kosa2 papers (2012–2013)Susan K. Paulson · AbbVie (United States)1 papers (2013–2013)Robert Löfberg · Karolinska Institutet1 papers (2012–2012)Mark T. Osterman · University of Alabama at Birmingham1 papers (2013–2013)Debra L. Miller · Fortius Clinic1 papers (2021–2021)Remo Panaccione · Nutrition-Génétique et Exposition aux Risques Environnementaux1 papers (2013–2013)